Automated quantitative RNA in situ hybridization for resolution of equivocal and heterogeneous ERBB2 (HER2) status in invasive breast carcinoma.

Patient management based on HER2 status in breast carcinoma is an archetypical example of personalized medicine but remains hampered by equivocal testing and intratumoral heterogeneity. We developed a fully automated, quantitative, bright-field in situ hybridization technique (RNAscope), applied it to quantify single-cell HER2 mRNA levels in 132 invasive breast carcinomas, and compared the results with those by real-time quantitative PCR (qPCR) and Food and Drug Administration-approved methods, including fluorescence in situ hybridization (FISH), IHC, chromogenic in situ hybridization, and dual in situ hybridization. Both RNAscope and qPCR were 97.3% concordant with FISH in cases in which FISH results were unequivocal. RNAscope was superior to qPCR in cases with intratumoral heterogeneity or equivocal FISH results. This novel assay may enable ultimate HER2 status resolution as a reflex test for current testing algorithms. Quantitative in situ RNA measurement at the single-cell level may be broadly applicable in companion diagnostic applications.

[1]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2014, Archives of pathology & laboratory medicine.

[2]  Berthold Streubel,et al.  Expression of HER2 and the Coamplified Genes GRB7 and MLN64 in Human Breast Cancer: Quantitative Real-time Reverse Transcription-PCR as a Diagnostic Alternative to Immunohistochemistry and Fluorescence In situ Hybridization , 2005, Clinical Cancer Research.

[3]  A. Jemal,et al.  Cancer statistics, 2011 , 2011, CA: a cancer journal for clinicians.

[4]  F. B. Sørensen,et al.  Real-time quantitative PCR of microdissected paraffin-embedded breast carcinoma: an alternative method for HER-2/neu analysis. , 2004, The Journal of molecular diagnostics : JMD.

[5]  Johannes Zimmermann,et al.  Automated analysis and detailed quantification of biomedical images using Definiens Cognition Network Technology. , 2009, Combinatorial chemistry & high throughput screening.

[6]  A. Tutt,et al.  A single-tube quantitative assay for mRNA levels of hormonal and growth factor receptors in breast cancer specimens. , 2009, The Journal of molecular diagnostics : JMD.

[7]  K. Allison,et al.  Achieving 95% cross-methodological concordance in HER2 testing: causes and implications of discordant cases. , 2010, American journal of clinical pathology.

[8]  A. Yosepovich,et al.  Breast cancer HER2 equivocal cases: is there an alternative to FISH testing? A pilot study using two different antibodies sequentially. , 2010, The Israel Medical Association journal : IMAJ.

[9]  L. Goldstein,et al.  Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[11]  M. J. van de Vijver,et al.  Microarray-Based Determination of Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Status in Breast Cancer , 2009, Clinical Cancer Research.

[12]  M. Hammond.  ASCO-CAP Guidelines for Breast Predictive Factor Testing: An Update , 2011, Applied immunohistochemistry & molecular morphology : AIMM.

[13]  J. Ross,et al.  Human epidermal growth factor receptor 2 testing in 2010: does chromosome 17 centromere copy number make any difference? , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  W. Jochum,et al.  HER2 genetic heterogeneity in breast carcinoma , 2011, Journal of Clinical Pathology.

[15]  T. Grogan,et al.  The Influence of Polysomy 17 on HER2 Gene and Protein Expression in Adenocarcinoma of the Breast: A Fluorescent In Situ Hybridization, Immunohistochemical, and Isotopic mRNA In Situ Hybridization Study , 2005, The American journal of surgical pathology.

[16]  M. Hidalgo,et al.  Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization method , 2011, Histopathology.

[17]  John M S Bartlett,et al.  Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J. Flanagan,et al.  RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. , 2012, The Journal of molecular diagnostics : JMD.

[19]  C. Sotiriou,et al.  Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer , 2006, Molecular Cancer Therapeutics.

[20]  D. Dabbs,et al.  High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Raymond R Tubbs,et al.  Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. , 2009, Archives of pathology & laboratory medicine.